Prolonged Complete Remission Using Tislelizumab for Hepatocellular Carcinoma After Adjuvant Chemotherapy Failure: A Case Report

References

• Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, staging, and management of hepatocellular Carcinoma: 2018 practice guidance by the American association for the study of liver diseases. Hepatology. 2018;68:723–750. doi:10.1002/hep.29913
   PubMed Web of Science ®Google Scholar
• Vogel A, Cervantes A, Chau I, et al. Hepatocellular carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29:iv238–iv255.
   PubMed Web of Science ®Google Scholar
• Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Zheng R, Qu C, Zhang S, et al. Liver cancer incidence and mortality in China: temporal trends and projections to 2030. Chin J Cancer Res. 2018;30:571–579. doi:10.21147/j.issn.1000-9604.2018.06.01
   PubMed Web of Science ®Google Scholar
• Villanueva A, Longo DL. Hepatocellular Carcinoma. N Engl J Med. 2019;380:1450–1462. doi:10.1056/NEJMra1713263
   PubMed Web of Science ®Google Scholar
• Li L, Zhang J, Liu X, et al. Clinical outcomes of radiofrequency ablation and surgical resection for small hepatocellular carcinoma: a meta-analysis. J Gastroenterol Hepatol. 2012;27:51–58. doi:10.1111/j.1440-1746.2011.06947.x
   PubMed Web of Science ®Google Scholar
• Tsilimigras DI, Bagante F, Moris D, et al. recurrence patterns and outcomes after resection of hepatocellular Carcinoma within and beyond the Barcelona clinic liver cancer criteria. Ann Surg Oncol. 2020;27:2321–2331. doi:10.1245/s10434-020-08452-3
   PubMed Web of Science ®Google Scholar
• Zhou Y, Ding J, Qin Z, et al. Predicting the survival rate of patients with hepatocellular carcinoma after thermal ablation by nomograms. Ann Transl Med. 2020;8:1159. doi:10.21037/atm-20-6116
   PubMed Web of Science ®Google Scholar
• Imamura H, Matsuyama Y, Tanaka E, et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol. 2003;38(2):200–207. doi:10.1016/S0168-8278(02)00360-4
   PubMed Web of Science ®Google Scholar
• Chan AWH, Zhong J, Berhane S, et al. Development of pre and post-operative models to predict early recurrence of hepatocellular carcinoma after surgical resection. J Hepatol. 2018;69:1284–1293. doi:10.1016/j.jhep.2018.08.027
   PubMed Web of Science ®Google Scholar
• Yao LQ, Chen ZL, Feng ZH, et al. Clinical features of recurrence after hepatic resection for early-stage hepatocellular carcinoma and long-term survival outcomes of patients with recurrence: A multi-institutional Analysis. Ann Surg Oncol. 2022.
   Google Scholar
• NCCN clinical practice guidelines in oncology (NCCN guidelines). Hepatob Canc Vers. 2023.
   Google Scholar
• Qin S, Chen M, Cheng AL, et al. Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2023;402:1835–1847. doi:10.1016/S0140-6736(23)01796-8
   PubMed Web of Science ®Google Scholar
• Ntellas P, Chau I. Updates on systemic therapy for hepatocellular carcinoma. Am Soc Clin Oncol Educ Book. 2024;44:e430028.
   PubMedGoogle Scholar
• Persano M, Rimini M, Tada T, et al. Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients. Eur J Cancer. 2023;192:113264. doi:10.1016/j.ejca.2023.113264
   PubMed Web of Science ®Google Scholar
• General Office of National Health Commission. Guidelines for diagnosis and treatment of primary liver cancer (2022 edition). J Clin Hepatol. 2022;38:288–303.
   Google Scholar
• Ren Z, Ducreux M, Abou-Alfa GK, et al. Tislelizumab in patients with previously treated advanced hepatocellular Carcinoma (RATIONALE-208): a Multicenter, Non-Randomized, Open-Label, Phase 2 Trial. Liver Cancer. 2023;12:72–84. doi:10.1159/000527175
   PubMed Web of Science ®Google Scholar
• Qin S, Kudo M, Meyer T, et al. Tislelizumab vs Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: a Phase 3 Randomized Clinical Trial. JAMA Oncol. 2023;9:1651–1659. doi:10.1001/jamaoncol.2023.4003
   PubMed Web of Science ®Google Scholar
• Patel TH, Brewer JR, Fan J, et al. FDA approval summary: Tremelimumab in combination with durvalumab for the treatment of patients with unresectable hepatocellular carcinoma. Clin Cancer Res. 2024;30:269–273. doi:10.1158/1078-0432.CCR-23-2124
   PubMed Web of Science ®Google Scholar
• Santoni M, Rizzo A, Mollica V, et al. The impact of gender on The efficacy of immune checkpoint inhibitors in cancer patients: The MOUSEION-01 study. Crit Rev Oncol Hematol. 2022;170:103596. doi:10.1016/j.critrevonc.2022.103596
   PubMed Web of Science ®Google Scholar
• Rizzo A, Brandi G. Biochemical predictors of response to immune checkpoint inhibitors in unresectable hepatocellular carcinoma. Cancer Treat Res Commun. 2021;27:100328. doi:10.1016/j.ctarc.2021.100328
   PubMedGoogle Scholar
• Mollica V, Rizzo A, Marchetti A, et al. The impact of ECOG performance status on efficacy of immunotherapy and immune-based combinations in cancer patients: the MOUSEION-06 study. Clin Exp Med. 2023;23:5039–5049. doi:10.1007/s10238-023-01159-1
   PubMed Web of Science ®Google Scholar
• De Marchi P, Leal LF, da Silva V D, et al. PD-L1 expression by tumor proportion score (TPS) and combined positive score (CPS) are similar in non-small cell lung cancer (NSCLC). J Clin Pathol. 2021;74:735–740. doi:10.1136/jclinpath-2020-206832
   PubMed Web of Science ®Google Scholar
• Qin S, Kudo M, Meyer T, et al. LBA36 Final analysis of RATIONALE-301: Randomized, Phase III study of tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma. Ann Oncol. 2022;33:S1402–S1403.
   Web of Science ®Google Scholar
• Yau T, Park JW, Finn RS, et al. LBA38_PR - CheckMate 459: a randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC). Ann Oncol. 2019;30:v874–v875. doi:10.1093/annonc/mdz394.029
   Web of Science ®Google Scholar
• Zhu AX, Finn RS, Edeline J, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol. 2018;19:940–952. doi:10.1016/S1470-2045(18)30351-6
   PubMed Web of Science ®Google Scholar
• Kudo M, Finn RS, Edeline J, et al. Updated efficacy and safety of KEYNOTE-224: a Phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib. Eur J Cancer. 2022;167:1–12. doi:10.1016/j.ejca.2022.02.009
   PubMed Web of Science ®Google Scholar
• Finn RS, Ryoo BY, Merle P, et al. pembrolizumab as second-line therapy in patients with advanced hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial. J Clin Oncol. 2020;38:193–202. doi:10.1200/JCO.19.01307
   PubMed Web of Science ®Google Scholar
• Kudo M, Lim HY, Cheng AL, et al. Pembrolizumab as second-line therapy for advanced hepatocellular carcinoma: a subgroup analysis of Asian patients in the phase 3 KEYNOTE-240 Trial. Liver Cancer. 2021;10:275–284. doi:10.1159/000515553
   PubMed Web of Science ®Google Scholar
• Qin S, Chen Z, Fang W, et al. Pembrolizumab versus placebo as second-line therapy in patients from Asia with advanced hepatocellular Carcinoma: A randomized, Double-Blind, Phase III Trial. J Clin Oncol. 2023;41(7):1434–1443. doi:10.1200/JCO.22.00620
   PubMed Web of Science ®Google Scholar
• Ponvilawan B, Roth MT. Sequencing Systemic Therapy in Hepatocellular Carcinoma. Curr Treat Options Oncol. 2023;24:1580–1597. doi:10.1007/s11864-023-01135-7
   PubMed Web of Science ®Google Scholar
• Johnson PJ, Dhanaraj S, Berhane S, Bonnett L, Ma YT. The prognostic and diagnostic significance of the neutrophil-to-lymphocyte ratio in hepatocellular carcinoma: a prospective controlled study. Br J Cancer. 2021;125:714–716. doi:10.1038/s41416-021-01445-3
   PubMed Web of Science ®Google Scholar
• Gibellini L, Borella R, Santacroce E, et al. Circulating and tumor-associated neutrophils in the era of immune checkpoint inhibitors: Dynamics, phenotypes, metabolism, and functions. Cancers (Basel). 2023;15:3327. doi:10.3390/cancers15133327
   PubMed Web of Science ®Google Scholar
• Mouchli M, Reddy S, Gerrard M, Boardman L, Rubio M. Usefulness of neutrophil-to-lymphocyte ratio (NLR) as a prognostic predictor after treatment of hepatocellular carcinoma”. Rev Arti Ann Hepa. 2021;22:100249. doi:10.1016/j.aohep.2020.08.067
   PubMed Web of Science ®Google Scholar
• Demirtas CO, D’Alessio A, Rimassa L, Sharma R, Pinato DJ. ALBI grade: Evidence for an improved model for liver functional estimation in patients with hepatocellular carcinoma. JHEP Rep. 2021;3:100347. doi:10.1016/j.jhepr.2021.100347
   PubMedGoogle Scholar
• Yu J, Li M, Ren B, et al. Unleashing the efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma: factors, strategies, and ongoing trials. Front Pharmacol. 2023;14:1261575. doi:10.3389/fphar.2023.1261575
   PubMed Web of Science ®Google Scholar
• Donne R, Lujambio A. The liver cancer immune microenvironment: therapeutic implications for hepatocellular carcinoma. Hepatology. 2023;77:1773–1796. doi:10.1002/hep.32740
   PubMed Web of Science ®Google Scholar
• Mathew AA, Zakkariya ZT, Ashokan A, et al. 5-FU mediated depletion of myeloid suppressor cells enhances T-cell infiltration and anti-tumor response in immunotherapy-resistant lung tumor. Int Immunopharmacol. 2023;120:110129. doi:10.1016/j.intimp.2023.110129
   PubMed Web of Science ®Google Scholar
• Xue Y, Gao S, Gou J, et al. Platinum-based chemotherapy in combination with PD-1/PD-L1 inhibitors: preclinical and clinical studies and mechanism of action. Expert Opin Drug Deliv. 2021;18:187–203. doi:10.1080/17425247.2021.1825376
   PubMed Web of Science ®Google Scholar
• Espana S, Perez Montes de Oca A, Marques-Pamies M, et al. Endocrine adverse events related to immune-oncology agents: retrospective experience of a single institution. Transl Lung Cancer Res. 2020;9:103–110. doi:10.21037/tlcr.2019.12.17
   PubMed Web of Science ®Google Scholar
• Wang D, Chen C, Gu Y, et al. Immune-Related Adverse Events Predict the Efficacy of Immune Checkpoint Inhibitors in Lung Cancer Patients: a Meta-Analysis. Front Oncol. 2021;11:631949. doi:10.3389/fonc.2021.631949
   PubMedGoogle Scholar
• Das S, Johnson DB. Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors. J Immunother Cancer. 2019;7:306. doi:10.1186/s40425-019-0805-8
   PubMed Web of Science ®Google Scholar
• Chan SL, Yip TC, Wong VW, et al. Pattern and impact of hepatic adverse events encountered during immune checkpoint inhibitors - A territory-wide cohort study. Cancer Med. 2020;9:7052–7061. doi:10.1002/cam4.3378
   PubMed Web of Science ®Google Scholar
• Zen Y, Yeh MM. Checkpoint inhibitor-induced liver injury: a novel form of liver disease emerging in the era of cancer immunotherapy. Semin Diagn Pathol. 2019;36:434–440. doi:10.1053/j.semdp.2019.07.009
   PubMed Web of Science ®Google Scholar
• Fessas P, Possamai LA, Clark J, et al. Immunotoxicity from checkpoint inhibitor therapy: clinical features and underlying mechanisms. Immunology. 2020;159:167–177. doi:10.1111/imm.13141
   PubMed Web of Science ®Google Scholar
• Gutierrez C, McEvoy C, Munshi L, et al. Critical care management of toxicities associated with targeted agents and immunotherapies for cancer. Crit Care Med. 2020;48:10–21. doi:10.1097/CCM.0000000000004087
   PubMed Web of Science ®Google Scholar